Yang W, Cai J, Shen S, et al. - Since vincristine plus dexamethasone pulses are generally used throughout maintenance treatment for childhood acute lymphoblastic leukaemia, however, previous studies remain uncertain about the benefit of this maintenance therapy and the absence of randomised, controlled trials in patients with low-risk or high-risk acute lymphoblastic leukaemia provides uncertainty, researchers conducted this open-label, multicentre, randomised, phase 3, non-inferiority trial to determine if this therapy could be safely omitted beyond 1 year of treatment without leading to an inferior outcome in any risk subgroup of childhood acute lymphoblastic leukaemia. This study enrolled 6,141 paediatric patients with newly diagnosed acute lymphoblastic leukaemia between January 1, 2015, and February 20, 2020. For children with low-risk acute lymphoblastic leukaemia, vincristine plus dexamethasone pulses may be skipped after one year of treatment.